法国胶质瘤患者补充与替代医学使用情况
该研究在法国九家中心于2017年5月至2018年5月期间,向WHO II-IV级、ECOG 0-2分的成人胶质瘤患者发放匿名问卷,调查补充与替代医学(CAM)使用情况。研究结论认为CAM在法国胶质瘤患者中使用频繁,应与患者及照护者讨论其需求、期望、与肿瘤治疗的潜在相互作用及经济与生活质量负担。
要点
- 68%的胶质瘤患者报告使用至少一种补充或替代医学方法。
- 补充治疗以维生素和食品补充剂为主,替代医学以磁疗和针灸为主。
- 14%改变饮食习惯者、25%补充治疗者、18%替代医学者月支出超过100欧元。
核心结论
- CAM在法国胶质瘤患者中使用频繁,应就潜在相互作用及经济与生活质量负担与患者和照护者讨论。
主要发现
- 135例(59%)为男性,中位年龄48岁,105例(46%)自报胶质母细胞瘤,99例(43%)自报复发疾病。
- 100例(44%)正在使用补充治疗,主要为维生素和食品补充剂;73例(32%)使用替代医学方法,主要为磁疗和针灸;总计154例(68%)报告使用至少一种方法。
- 月支出超过100欧元的用户比例:改变饮食习惯者14%,补充治疗者25%,替代医学者18%。
- 所有方法普遍被认为可改善生活质量且体验为有效,尤其是与更高支出相关的方法。
临床怎么用
- 临床中应主动询问胶质瘤患者CAM使用情况,并讨论其需求、期望及与肿瘤特异性治疗的潜在相互作用。
- 关注CAM相关的经济负担与生活质量影响,并与患者及照护者沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Complementary and alternative medicine (CAM) use increases in cancer patients, including adult patients with diffuse gliomas. METHODS: Questionnaires addressing CAM use were distributed to adult patients with gliomas of WHO grades II-IV and ECOG performance score of 0-2 during hospital visits and filled in anonymously. The study was conducted in nine centers in France from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses according to gender, age, WHO grade, and recurrent versus newly diagnosed disease were conducted. RESULTS: Two hundred twenty-seven questionnaires were collected; 135 patients (59%) were male. Median age was 48 years, 105 patients (46%) declared having glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three patients (45%) had modified their alimentary habits after the glioma diagnosis. At the time of the questionnaire, 100 patients (44%) were on complementary treatment, mainly vitamins and food supplements, and 73 patients (32%) used alternative medicine approaches, mainly magnetism and acupuncture. In total, 154 patients (68%) declared using at least one of these approaches. Expenditures exceeding 100 € per month were reported by users in 14% for modification of alimentary habits, in 25% for complementary treatment, and in 18% for alternative medicines. All approaches were commonly considered as improving quality of life and experienced as efficient, notably those associated with more expenditures. CONCLUSIONS: CAM are frequently used by glioma patients in France. Underlying needs and expectations, as well as potential interactions with tumor-specific treatments, and financial and quality of life burden, should be discussed with patients and caregivers.
引用
- Le Rhun E, Devos P, Bourg V, et al. Complementary and alternative medicine use in glioma patients in France. J Neurooncol. 2019. PMID: 31637628. doi:10.1007/s11060-019-03315-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。